



APCCC Detailed Programme 2017 (subject to minor changes)

Areas of controversy

1. Management of castration-sensitive/naive prostate cancer
2. Management of castration-resistant prostate cancer (CRPC): M0 disease management and sequencing/combination treatment for metastatic CRPC
3. Use of novel imaging modalities
4. Molecular characterization: Tissue and blood based biomarkers in daily clinical practice
5. Germline mutations
6. Management of high risk and locally advanced prostate cancer
7. Oligometastatic and oligo-progressive prostate cancer
8. Supportive care and side effects of treatment
9. Patient reported outcomes
10. Global access to prostate cancer drugs and treatment in countries with limited resources

Thursday 9th March 2017

Time	Session	
09:00	Welcome Address Silke Gillissen and Aurelius Omlin on behalf of APCCC	
9:15 -10:30 Session 1	Castration-sensitive/naive prostate cancer: Part 1	Chairs: Chris Sweeney and Mack Roach
	Definition: Castration-sensitive/naive prostate cancer	Howard Scher
	When and how to use salvage radiation therapy in biochemical recurrence?	Alberto Bossi
	When and what hormonal therapy to use for men with castration-sensitive/naive prostate cancer and isolated biochemical recurrence (M0) after radical treatment?	Martin Gleave
	Systemic treatment for men with high-risk and locally-advanced prostate cancer treated with curative intent	Nick James
Coffee Break		
11:00 – 12:30 Session 2	Castration-sensitive/naive prostate cancer: Part 2	Chairs: Karim Fizazi and Pirkko Kellokumpu-Lehtinen and Matt Sydes
	Review of the status of ongoing and unreported clinical trials in the M1 castration-sensitive/naive space	Celestia Higano
	Should we be lumpers or slicers?	Susan Halabi
	Point/counterpoint: Chemo-hormonal therapy should be used for all men with castration-sensitive/naive M1 disease fit for chemotherapy: <ul style="list-style-type: none"> • Pro • Contra • Arbiter 	Pro: Chris Parker Contra: Ian Tannock Arbiter: William Oh
	Is there a role for treating the primary in patients with metastatic disease?	Axel Heidenreich
	Your patient received ADT plus docetaxel for M1 castration-sensitive/naive disease - now what?	Chris Sweeney
12:30 – 13:30 LUNCH		
13:30 – 15:00 Session 3	CRPC M0 and M1: Sequencing and Combination Therapy	Chairs: Eleni Efstathiou and Ian Davis
	Castration-resistant prostate cancer – where are the questions?	Eleni Efstathiou
	M0 CRPC: Does it still exist and if yes, to treat or not to treat?	Brett Carver
	What is the optimal time to change treatment in men with mCRPC?	Karim Fizazi
	Point/counterpoint: AR-V7 – ready for use in daily clinical decision making? <ul style="list-style-type: none"> ○ Pro ○ Contra ○ Arbiter 	Pro: Phil Kantoff Contra: Tom Beer Arbiter: Chris Evans
	Take home message	Ian Davis



ADVANCED PROSTATE CANCER CONSENSUS CONFERENCES

St. Gallen / Switzerland 9 – 11 March 2017

COFFEE BREAK		
15:30 – 16:30 Session 4	Molecular characterization Part 1	Chairs: Ros Eeles and Howard Soule
	Next-generation or targeted sequencing of germline and somatic DNA in men with CRPC	Colin Pritchard
	Patients with familial prostate cancer – practical implications and recommendations	Ros Eeles
COFFEE BREAK		
17:00 – 18:45 Session 5	Molecular characterization Part 2:	Chairs: Mark Rubin, Johann de Bono, Gert Attard
	Aggressive variants of prostate cancer: When to look for it and how to treat it?	Himisha Beltran
	Tumour biopsy in men with metastatic prostate cancer: What the pathologist should report?	Mark Rubin
	Taking action on molecular subtypes	Johann de Bono
	Plasma based biomarkers in APC	Gert Attard
	Circulating tumour cells – ready for prime time?	Howard Scher

Friday 10 th March 2017		
Time	Session	Chair & Speakers
Extra session 08:00 – 08:20	Outcomes Research – Ironman project	Chair: Phil Kantoff
	International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)	Lorelei Mucci
08:30 – 10:00 Session 6	MOVEMBER SESSION: Global view on APC and access to novel drugs	Chairs: Ian Tannock and Gedske Daugaard and Raja Khauli
	Availability of drugs (including pain medication): A major problem for the Global Fight against Cancer	Franco Cavalli
	Epidemiology and Treatment of APC in India	Vedang Murthy
	Epidemiology and Treatment of APC in Asian countries	Byung Ha Chung
	Epidemiology and Treatment of APC in South America	Fernando Maluf
	Pharmacokinetics and tolerance of prostate cancer drugs in Japan and other Asian countries	Hiroyoshi Suzuki
	Best use of “old and cheap” drugs	Ian Tannock
	Chair’s summary, panel discussion and questions	
COFFEE BREAK		
10:30 – 12:00 Session 7	Localised prostate cancer	Chairs: Neal Shore and Avi Sella and Axel Heidenreich
	New imaging modalities for men with high-risk and locally-advanced prostate cancer: What are the clinician’s expectations?	Mark Frydenberg
	Local therapy in high-risk and locally-advanced prostate cancer <ul style="list-style-type: none"> • What is optimal surgery? • What is optimal radiation therapy? 	Nicolas Mottet Mack Roach
	Quality control and standardisation of reporting for radical prostatectomy in locally-advanced disease: <ul style="list-style-type: none"> • What information the clinician needs from his pathologist? • Pathologists reply 	Neal Shore Mark Rubin
	Adjuvant treatment in men with unfavourable pathology after radical prostatectomy	Rob Bristow
12:00 – 13:00 LUNCH		
13:00 – 14:30 Session 8	Supportive care and side effects of treatment	Chairs: Ian Davis and Matthew Smith and Daniel Castellano
	Prevention and treatment of side effects of ADT	Matthew Smith
	Management of chronic pre-existing or treatment-emergent adverse events of the other systemic therapies	Michael Morris



ADVANCED PROSTATE CANCER CONSENSUS CONFERENCES

St. Gallen / Switzerland 9 – 11 March 2017

Patient-reported outcome measures: How to use them in daily practise?		Alicia K. Morgans
Point/counterpoint: Bone targeted therapy with zoledronate or denosumab is required in men with metastatic CRPC responding to anticancer therapy: <ul style="list-style-type: none"> • Pro • Contra • Arbiter 		Pro: Fred Saad Contra: Noel Clarke Arbiter: Cora Sternberg
Involvement of the extended multidisciplinary management team		Ian Davis
COFFEE BREAK		
15:00 – 16:30 Session 9	Oligometastatic and oligo-progressive prostate cancer (castration-sensitive/naive and CRPC)	Chairs: Oliver Sartor and Piet Ost and Bertrand Tombal
Overview and definition		Piet Ost
Imaging What are the clinician's needs in this situation? ➤ Answer of the nuclear medicine specialist ➤ Answer of the radiologist		Oliver Sartor Stefano Fanti Anwar Padhani
Treatment of men with oligometastatic disease – Debate: <ul style="list-style-type: none"> • Multimodality treatment (local treatment all metastases +/- primary + systemic treatment) • Local treatment alone (surgical or radiation) of all lesions • No local treatment, systemic therapy alone (or watch and wait) • Arbiter: In the absence of good evidence, what to do in daily practice? 		Chuck Ryan Felix Feng Nicholas Mottet Robert Bristow
Strategies for oligo-progressive CRPC		Bertrand Tombal
COFFEE BREAK		
17:00 – 18:30 Session 10	ESO OBSERVATORY: What will change for men with advanced prostate cancer in the next 24 months?	Chair: Riccardo Valdagni and Silke Gillessen
<ul style="list-style-type: none"> • Perspective on molecular characterization • Perspective on imaging (PET and MRI) • Perspective on endocrine and chemotherapy agents • Perspective on immunotherapy • Perspective on novel agents (including PARP inhibitors) • Perspective on radiation therapy • Perspective on surgery • Patients perspective 		Himisha Beltran Gero Kramer Cora Sternberg Chuck Drake Chris Logothetis Thomas Wiegel Borges Dos Reis Rodolfo Ken Mastris

Saturday 11 th of March 2017		
Time	Special Session	Speakers
	All participants will be able to attend the panel meeting as part of the conference.	
08:30 – 10:30	Consensus Panel – Discussion and votes on consensus questions – Part 1	ALL PANEL MEMBERS Moderation: Bertrand Tombal and Matthew Smith
COFFEE BREAK		
11:00 – 13:00	Consensus Panel – Discussion and votes on consensus questions – Part 2	ALL PANEL MEMBERS Moderation: Bertrand Tombal and Matthew Smith
Closing Remarks: S.Gillessen and A.Omlin		